Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
11/19/2002Meridian Bioscience Announces Dividend Actions and Provides Guidance for Fiscal 2003
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Nov. 19, 2002--Meridian Bioscience, Inc., (Nasdaq:VIVO) today (i) declared the regular cash dividend for the fourth quarter ended September 30, 2002, (ii) increased the regular cash dividend rate for fiscal 2003, and adopted a new cash dividend policy; and (iii) provided guidance to the financial community with respect to its operating projections for the current fiscal year ending September 30, 2003 as follows: Fisca... 
 Printer Friendly Version
11/13/2002Meridian Bioscience Reports Fiscal 2002 Year End and Fourth Quarter Operating Results
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Nov. 13, 2002--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today reported operating results for the fourth quarter and fiscal year ended September 30, 2002. Fiscal Year 2002 Net sales for fiscal 2002 were $59,104,000 as compared to $56,527,000 for fiscal 2001, an increase of $2,577,000 or 4.6%. Net income for fiscal 2002 was $5,031,000, $0.34 per diluted share, compared to a loss of $10,275,0... 
 Printer Friendly Version
11/8/2002Meridian Bioscience and Biotrin Holdings Terminate Acquisition Talks
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Nov. 8, 2002--Meridian Bioscience, Inc.,(Nasdaq:VIVO) today announced that it and Biotrin Holdings plc have terminated negotiations and ceased further discussions regarding Meridian Bioscience's earlier interest in acquiring Biotrin Holdings. Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related pr... 
 Printer Friendly Version
10/7/2002Meridian Reports on Biotrin Progress
CINCINNATI, Oct 7, 2002 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced it is continuing its pre-acquisition due diligence review of Biotrin Holdings plc, an Irish-based diagnostics company, and is concurrently in the process of negotiating a definitive stock purchase agreement. Although there can be no assurances that this previously announced contemplated acquisition will take place, progress is being made and it is anticipated that the purchase of Biotrin will... 
 Printer Friendly Version
7/23/2002Meridian Reports Profitable Third Quarter Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2002 Guidance and Comments On Other Subjects
CINCINNATI, Jul 23, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) EPS of $0.11 reported for the third quarter of fiscal year 2002 compared to ($0.04) in the prior year period EPS of $0.28 reported for the first nine months of fiscal year 2002 compared to ($0.72) in the prior year period Fiscal year 2002 EPS estimate of $0.38 to $0.43 reaffirmed Strong EBITDA and positive cash flow in fiscal year 2002 Bi... 
 Printer Friendly Version
7/22/2002Meridian Commences Distribution of New Rapid Test for Stomach Ulcers
CINCINNATI, Jul 22, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has begun international distribution of its patent protected ImmunoCard Stat! HpSA rapid test for Helicobacter pylori bacteria, the primary cause of stomach ulcers. The ImmunoCard STAT! HpSA test is highly accurate, simple to perform, and yields results in just five minutes. The speed and simplicity of the test makes it ideal for use in quickly diagnosing, treating and monitoring su... 
 Printer Friendly Version
7/18/2002Meridian Announces Japanese Market Launch of Rapid Adenovirus Test
CINCINNATI, Jul 18, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its Japanese distributor, TFB, Inc. of Tokyo, Japan has begun distribution of Meridian's ImmunoCard STAT!(R) Adenovirus test, having received approval to market by the Japanese Ministry of Health. ImmunoCard STAT! Adenovirus is a rapid point-of-care test that can be used in a physician's office to directly detect the virus that can cause conjunctivitis, pharyngitis, or... 
 Printer Friendly Version
5/23/2002Meridian Signs Agreement in Principle to Acquire Biotrin Holdings plc
CINCINNATI--(BW HealthWire)--May 23, 2002--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced it has executed a letter of intent to acquire all the outstanding capital stock of Biotrin Holdings plc, headquartered in Dublin, Ireland. The purchase price includes cash and possible future earnout opportunities, the amounts of which were not disclosed. The transaction is expected to be completed within 45 days. Biotrin develops, manufactures and sells lead... 
 Printer Friendly Version
5/14/2002Meridian Appoints PricewaterhouseCoopers LLP as Its Independent Public Accountants
CINCINNATI, May 14, 2002 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it has appointed PricewaterhouseCoopers LLP as the Company's Independent Certified Public Accountants for fiscal year 2002. This appointment is the culmination of an extensive two-month evaluation and selection process involving the Audit Committee of the Board of Directors and executive management. William J. Motto, Chairman and Chief Executive Officer, stated, "We believe the Pric... 
 Printer Friendly Version
4/23/2002Meridian Reports Profitable Second Quarter Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2002 Guidance and Comments On Other Subjects
CINCINNATI, Apr 23, 2002 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO): Second quarter EPS of $0.10 reported First half EPS of $0.18 reported Full year EPS of $0.38 to $0.43 reaffirmed Record EPS for fiscal 2003 expected Strong EBITDA and positive cash flow Fully funded internal business plan Solid financial condition No impairment charges under SFAS 142 Life science progress Acquisition search underw... 
 Printer Friendly Version
3/28/2002Meridian's Patented Premier HpSA Stomach Ulcer Test Subject of Article in Annals of Internal Medicine
CINCINNATI, Mar 28, 2002 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that an important drug eradication study of its Premier HpSA(R) (stomach ulcer) test has been published in an article entitled, "The Stool Antigen Test for Detection of Helicobactor pylori after Eradication Therapy," (Dr. D. Vaira, Dr. N. Vakil, et al.). Appearing in the February 19, 2002, issue of the Annals of Internal Medicine, the article reports on a study designed to determine wheth... 
 Printer Friendly Version
1/22/2002Meridian Bioscience Reports Favorable First Quarter Operating Results, Declares Regular Cash Dividend, and Reaffirms EPS Guidance for Fiscal 2002
CINCINNATI, Jan 22, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced net earnings of $1,187,000, or $0.08 per fully diluted share for the first quarter ended December 31, 2001. This compares with a net loss of $8,192,000, or $0.56 per share for the same period of the prior fiscal year. Net sales for the first quarter of this fiscal year were $13.6 million compared to $15.3 million for the first quarter of the prior fiscal year, a decline of approximately ... 
 Printer Friendly Version
1/9/2002Meridian Bioscience's Helicobacter pylori -- Stomach Ulcers -- Technology Granted European Patent
CINCINNATI, Jan 9, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has been granted a patent in Europe covering its innovative technology for detecting the primary causative agent for stomach ulcers, Helicobacter pylori. This technology, which is the basis for the Premier Platinum HpSA(TM) test, was granted the first of its United States' patents in February 1998. Premier Platinum HpSA was the first noninvasive direct test for Helicobacter pylor... 
 Printer Friendly Version
1/7/2002Meridian Announces April 2002 Availability of Its Biopharmaceutical Production Facilities
CINCINNATI, Jan 7, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO), today announced that its wholly-owned subsidiary Viral Antigens, Inc. (VAI), has initiated a marketing campaign, based upon direct mail, personal contacts and an upgraded website (www.viralantigens.com), designed to communicate the anticipated availability of its new biopharmaceutical production laboratories. The Memphis, Tenn.-based VAI is combining 20 years of cell culture expertise with... 
 Printer Friendly Version